Advances in the preclinical testing of cancer therapeutic hypotheses
The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.
Abstract
The genetic and epigenetic underpinnings of cancer are becoming increasingly clear owing to impressive and well-coordinated ventures occurring worldwide. As our understanding of the molecular alterations driving human cancer increases, there is an opportunity to direct the clinical application of cancer therapeutics with improved accuracy. The often empirical treatment of cancer--which was initially based on inhibiting DNA synthesis and cellular division--while having led to a number of remarkable successes, remains prone to a high rate of clinical failure that results partly from a lack of understanding of how best to implement drugs in the clinic. Consequently, it is vital that robust translational strategies be developed preclinically to both reduce failure rates in the clinic and shorten the time required to identify patient populations most likely to benefit from a given therapeutic. Here, we review both historical and current uses of preclinical model systems, being mindful that a combination of approaches will be needed to address all meritorious therapeutic hypotheses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Such mutations were initially identified through the study of samples taken from patients with relapsed diseas”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“, as well as a variety of lesions in oncogenic driver genes including KRAS , epidermal growth factor receptor ( EGFR ), phosphoinositide 3-kinase, catalytic, alpha polypeptide (PI3KCA) and anaplastic lymphoma receptor tyrosine kinase (ALK), among other”
BackgroundThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Research works printed but not linked: 2
- Fantini, A., Moser, L., Partridge, R. & Halliday, J. L. The effect of actinomycin D on several mouse tumors. Proc. Am. Assoc. Cancer Res. 2, 108 (1956).
- Farber, S. Carcinolytic action of antibiotics: puromycin and actinomycin D. Am. J. Pathol. 31, 582 (1955).
Cited by
Items 101–165 of 165
Advances in prostate cancer research models: From transgenic mice to tumor xenografting models
Huang, Y., Cheng, C., Zhang, C., Zhang, Y., Chen, M., Strand, D. W., & Jiang, M. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.02.004 · Cited by 9
“Firstly, tumorehost interactions are not always conserved across species and functional human immunity is mostly absent in host mice [134].”
BackgroundYang, D. S. (2014) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2014.6944693 · Cited by 9
Greek, R., & Hansen, L. A. (2012) · Biological Systems Open Access · doi:10.4172/2329-6577.1000109 · Cited by 14
Shu, D., Shen, M., Li, K., Han, X., Han, L., Tan, Z., Wang, Y., Peng, Y., Tang, Z., Qu, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1060052/v1 · Cited by 9
Liu, P., Zhou, S., Zhou, Z., Jin, Z., Chen, W., Li, Z., Xu, J., Chen, F., Li, Y., Wen, Y., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217582 · Cited by 8
Colon cancer cells evade drug action by enhancing drug metabolism
Cong, B., Thakur, T., Uribe, A. H., Stamou, E., Gopinath, S., Sansom, O. J., Maddocks, O. D. K., & Cagan, R. L. (2025) · Oncogene · doi:10.1038/s41388-025-03472-3 · Cited by 9
“One important factor that has emerged is the role of genetic complexity: drug resistance typically increases in preclinical models that are more genetically complex [2, 3].”
Esophageal organoids: applications and future prospects
Liu, H., & Wang, X. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02340-5 · Cited by 10
“Meanwhile, drugs tested in 2D cell lines and animal models have a high failure rate in clinical trials due to the difficulty of these conventional models to fully simulate the characteristics of the primary tumor [103].”
BackgroundMetastatic disease: A drug discovery perspective
Lehembre, F., & Regenass, U. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.005 · Cited by 9
Advance in Human Epithelial-Derived Organoids Research
Li, F., Zhang, P., Wu, S., Yuan, L., & Liu, Z. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00452 · Cited by 8
Jiang, W., Mautner, V., Friedrich, R. E., & Kluwe, L. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.172 · Cited by 8
Assessing Specificity of Anticancer Drugs In Vitro
Kluwe, L. (2016) · Journal of Visualized Experiments · doi:10.3791/53752 · Cited by 8
“This study illustrates the procedure of the genetic and cell-based tool for assessing specificity of anticancer drugs including (1) preparing a mixed culture from tumor cells of an established line and non-tumor fibroblasts, (2) treating the mixed culture with a test drug, (3) preparing DNA for digital PCR, (4) determ…”
MethodCui, T., Wang, Z., Gu, H., Qin, P., & Wang, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1095976 · Cited by 7
“Moreover, portable algorithm development is a hot topic in this area (Caponigro and Sellers, 2011; Garnett et al., 2012; Wei et al., 2019).”
BackgroundEmerging horizons of AI in pharmaceutical research
Bachhar, S., Kumar, S. P. J., Dutta, B., & Das, S. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.01.016 · Cited by 6
Singh, D., & Bedi, N. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70036 · Cited by 6
Shao, C., Ju, S., Tong, X., Hu, K., Yu, L., Zhu, Y., Yang, J., Li, C., Xie, Y., Cui, Y., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70534 · Cited by 6
“9 Organoids, three-dimensional (3D) cell culture based in vitro models, offer an advanced system that closely mimics the structural and functional properties of native tissues or organs in vivo.”
Patient-derived rectal cancer organoids—applications in basic and translational cancer research
Yan, Y., Cheong, I. H., Chen, P., Li, X., Wang, X., & Wang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.922430 · Cited by 7
“(2-4) *10^4 cells/ ul Not mentioned Culture medium was changed every 3 days.”
BackgroundFang, L., Liu, Y., Zhang, Y., Pan, Z., Zhong, L., Jiang, L., Wang, J., Zheng, X., Chen, L.-Y., Huang, P. C., et al. (2021) · Journal of Cancer · doi:10.7150/jca.50897 · Cited by 6
“These efforts are limited by lack of understanding about molecular details of cancer cells [22], and they have been less successful with thyroid cancer.”
Bibliometric analysis of global research on human organoids
Li, H., Wang, D., Ho, C. W., & Shan, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27627 · Cited by 8
Ocaña, A., Freedman, O. C., Amir, E., Šeruga, B., & Pandiella, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9451-7 · Cited by 6
The Path to Oncology Drug Target Validation: An Industry Perspective
Cortés-Cros, M., Schmelzle, T., Stucke, V. M., & Hofmann, F. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-311-4_1 · Cited by 7
WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer
Cong, B., Stamou, E., Pennel, K. A. F., Thakur, T., McKenzie, M., Matly, A., Gilroy, K. L., Shah, H., Gopinath, S., Edwards, J., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00588-1 · Cited by 7
“One source of drug resistance is genetic complexity, a consistent and key hallmark of CRC (Caponigro and Sellers, 2011; Bangi et al, 2016; Wang et al, 2022).”
Computational Study of Radiopharmaceuticals
Demir, E., Özgenç, E., Ekinci, M., Gündoğdu, E., İlem‐Özdemir, D., & Aşıkoğlu, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85140 · Cited by 7
Rawat, S. J., Sharma, Y., Majood, M., & Mohanty, S. (2023) · Biochemistry · doi:10.5772/intechopen.109671 · Cited by 5
Kluwe, L., Jiang, W., Alster, I., & Hanken, H. (2015) · Biomedical Papers · doi:10.5507/bp.2015.057 · Cited by 5
Richter‐Pechańska, P., Becker, M., Mayr, T., Hinzmann, B., Adams, H.-P., Klaman, I., Kretschmar, K.-H., Kretschmar, K., Stecker, K., Mantke, R., et al. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.42083 · Cited by 5
“the NCI60 panel) have been used for testing investigational drugs and to explore potential biomarkers [30].”
BackgroundMethodA DFX-based iron nanochelator for cancer therapy
Liu, P., Wang, Q., Li, K., Bi, B., Wen, Y., Qiu, M., Zhao, J., Li, B., Zhang, C., & He, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1078137 · Cited by 5
“However, variations between cell lines and original tumors are responsible for the failure of the drug-based clinical trials (Kamb, 2005; Caponigro and Sellers, 2011; Barretina et al., 2012).”
BackgroundOrganoid Technology and Clinical Applications in Digestive System Cancer
Zhao, X., Jiang, Y., Liu, C., Hou, M., Wang, H., & Fu, J. (2021) · Engineering · doi:10.1016/j.eng.2021.04.017 · Cited by 4
Applications and limitations of pluripotent stem cell-derived liver organoids
Feng, Z., Zhou, B., Shuai, Q., Mu, J., & Xie, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003707 · Cited by 6
“[4,69] PHHs, considered the “gold standard” for drug efficacy and toxicity evaluation, [70] have limitations in terms of availability, proliferation in vitro , and relevance to non-parenchymal liver cells, which are crucial in many liver diseases.”
Microflow LC‐MS for Quantitative Analysis of Drugs in Support of Microsampling
Skor, H. E., & Rahavendran, S. V. (2013) · doi:10.1002/9781118671276.ch50 · Cited by 4
Kim, Y., Park, D., Lee, D. H., & Chung, C. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114642 · Cited by 3
Greek, R. (2014) · Biological Systems Open Access · doi:10.4172/2329-6577.1000124 · Cited by 3
“Moreover, the use of animal models for testing safety and efficacy of drugs in general has been studied and animal models have failed the test [109,169-172,174,324-350].”
BackgroundThree-dimensional tumor model and their implication in drug screening for tackling chemoresistance
Priyadarshini, M., Mohanty, S., Mahapatra, T., Mohapatra, P., & Dash, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818128-7.00020-4 · Cited by 3
Three Dimensional Tissue Models for Research in Oncology
Nietzer, S., Dandekar, G., Wasik, M. A., & Walles, H. (2012) · InTech eBooks · doi:10.5772/33600 · Cited by 3
“For example, the Novartis Institutes for BioMedical Research in collaboration with other investigators assembled in the “Cell Line Encyclopedia Project“ expression profiles, copy-number alterations and doseresponse data of over 1000 cell lines (Caponigro & Sellers, 2011).”
BackgroundMethodInfluentialA stability-driven protocol for drug response interpretable prediction (staDRIP)Preprint
Li, X., Tang, T. M., Wang, X., Kocher, J. P. A., & Yu, B. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2011.06593 · Cited by 3
“[8] Giordano Caponigro and William R Sellers.”
Patient-Derived Bladder Cancer Organoids: Model Construction and Drug Sensitivity Testing
Liu, R., Zhang, Y., & Zhou, Z. (2025) · Urologia Internationalis · doi:10.1159/000543983 · Cited by 3
Research Advances and Disease Modeling in Respiratory Organoids
Chu, L., Chen, D., Jiang, S., Long, H., Liu, X., & Chen, Y. (2026) · Biomedicines · doi:10.3390/biomedicines14010221 · Cited by 2
“Traditional 2D cell culture systems have often led to the identification of anti-cancer drugs that exhibit limited efficacy in clinical trials [160].”
AI Driven Computational Nanomedicine for Personalized Cancer Therapy
Farghama, K., Khan, M. S., Wajid, M., & Shaffique, S. (2026) · BioNanoScience · doi:10.1007/s12668-026-02681-8 · Cited by 2
“Moreover, in silico drug screening techniques help priori - tize candidate compounds in preclinical research, optimize trial planning, and save expenses (Caponigro & Sellers, 2011 ).”
Sur, C. (2019) · Data-Enabled Discovery and Applications · doi:10.1007/s41688-019-0035-8 · Cited by 2
Novel Drug Screening Platform: Tumor Organoid
Maeng, J. E., Seo, H., Kim, S., & Ku, J. (2021) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2021.26.4.233 · Cited by 2
Culture, Manipulation, and Orthotopic Transplantation of Mouse Bladder Tumor Organoids
Kim, Y., Lee, J., Kim, S., & Shin, K. (2020) · Journal of Visualized Experiments · doi:10.3791/60469 · Cited by 2
Zhou, P., Mills, C. B., Dong, Z. M., Barber, B. R., & Beronja, S. (2025) · Cancer Medicine · doi:10.1002/cam4.71137 · Cited by 1
Using Systems Pharmacology to Advance Oncology Drug Development
Kirouac, D. C. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_19 · Cited by 2
Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment
Ward, C., Meehan, J., Gray, M., Kunkler, I. H., Langdon, S. P., Murray, A., & Argyle, D. J. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_159 · Cited by 2
Separating Response of Tumor and non-Tumor Cells to Drug In Vitro by Quantifying a Mutation
Kleinpoppen, M., Moebius, C., Grupp, K., Kluwe, L., & Blessmann, M. (2019) · Anticancer Research · doi:10.21873/anticanres.13284 · Cited by 1
Assessing Specificity of Anticancer Drugs In Vitro
Kluwe, L. (2016) · Journal of Visualized Experiments · doi:10.3791/53752-v · Cited by 6
Culture, Manipulation, and Orthotopic Transplantation of Mouse Bladder Tumor Organoids
Kim, Y., Lee, J., Kim, S., & Shin, K. (2020) · Journal of Visualized Experiments · doi:10.3791/60469-v · Cited by 1
Chick Early Amniotic Fluid (ceAF) Deters Tumorigenesis via Cell Cycle Arrest and Apoptosis
Ahmad, M., Yu, J., Cheng, S., Khan, Z. A., Luo, Y., & Luo, H. (2022) · Biology · doi:10.3390/biology11111577 · Cited by 1
“As a result, many drugs that perform well in the cancer case study led to ultimate failure in clinical trials [3].”
BackgroundDr.Paso: Drug response prediction and analysis system for oncology researchPreprint
Azuaje, F. J., Kaoma, T., Jeanty, C., Nazarov, P. V., Muller, A., Kim, S., Golebiewska, A., Dittmar, G., & Niclou, S. P. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/237727 · Cited by 1
“The unbiased, large-scale prediction of anticancer drug activity using tumor-derived molecular data is crucial to deliver on the promise of a more personalized, precise treatment of cancer patients (Caponigro and Sellers, 2011; Ross and Wilson, 2014).”
BackgroundArava, M., Sivankutty, I., Kim, J. H., An, Z., Hilal, N., Matsui, E., Sahu, D., Cai, C., Behrsing, H., Gerlovin, K., et al. (2026) · Disease Models & Mechanisms · doi:10.1101/2025.04.22.649643 · Cited by 2
In Vitro Sensitivity Testing in the Assessment of Anti-CLL Drug Candidates
Krause, G., Kuckertz, M., Kerwien, S., Patz, M., & Hallek, M. (2012) · InTech eBooks · doi:10.5772/27087
“…the importance of accompanying signaling analysis, consideration of the micro-environment of CLL cells and combination with chemotherapeutic agents conceptually strongly overlap with general targeting strategies in contemporary pre-clinical anticancer drug discovery (Caponigro & Sellers, 2011).”
BackgroundPreclinical evaluation of a novel drug delivery system for cisplatin
Venugopal, B. (2012) · Enlighten: Theses (The University of Glasgow)
Cancer cell line encyclopedias
Fulmer, T. (2012) · Science-Business eXchange · doi:10.1038/scibx.2012.431
McCubrey, J. A., Steelman, L. S., Bäsecke, J., & Martelli, A. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_14
Introduction to Organ Fabrication
Birla, R. K. (2016) · Learning materials in biosciences · doi:10.1007/978-3-319-41504-8_1
The Importance of Circulating Tumor Cells and Tumor Models in Future of Cancer Therapy
Behnam, B., Fazilaty, H., & Roghanian, A. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-45397-2_7
PDX Models of Colorectal Tumors
MacKeigan, J. P., & Burgenske, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00021-7
Investigation of the Role of Tensile Forces in Cellular Response to Chemotherapeutic Agents
Schmitt, S. (2016) · KU ScholarWorks (University of Kansas)
Penalized Estimation Methods and Their Applications in Genomics and Beyond
Chen, T. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/e37z-6f04
Leveraging technological opportunities in cancer genomics
Valle-Inclán, J. E. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/480
Therapeutic applications of three-dimensional organoid models in lung cancer
Yeo, C. D., Yun, Y.-P., Ahn, D. H., Hwang, Y., Yang, S. H., Won, H., Cho, H. J., Park, C. K., Kim, S. J., & Park, J. Y. (2021) · Organoid · doi:10.51335/organoid.2021.1.e6 · Cited by 1
“In the past decades, many anti-cancer drugs developed by screening traditional 2D cell cultures as preclinical disease model system have proven to be ineffective in clinical studies [93].”
Drug Discovery Platform Using Organoids
Maeng, J. E., Kim, S., Song, M.-H., Jeong, N., & Ku, J. (2022) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2022.10.2.82
Monleón-Guinot, I., Bravo-Baranda, L., Milián, L., Sancho‐Tello, M., Llop-Miguel, M., Galbis, J. M., Cremades, A., Cardá, C., & Mata, M. (2024) · Cells Tissues Organs · doi:10.1159/000541524
“Moreover, cancer cell lines generally do not maintain the genetic heterogeneity of the original tumors [13 – 15].”
Identification of genomic markers for drug sensitivity using Multi-task Learning
Aben, N. (2014) · Research Repository (Delft University of Technology)
Ulvé, R. (2016) · theses.fr (ABES) · doi:10.70675/3e61a67dzc29bz41eczadebz4bb815a9dca7 · Cited by 1
Moragheb, M. A., Dehghan, A., Razzaghi, P., & Gharaghani, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348908
Metadata
- Authors
- Caponigro, G., & Sellers, W. R.
- Corresponding author
- Caponigro, Giordano
- ORCID
- Sellers, William R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 179-187
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2091336659
- Cited by
- 165
- References
- 89
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 8 · 2023: 11 · 2022: 14 · 2021: 18 · 2020: 10 · 2019: 15 · 2018: 7 · 2017: 4 · 2016: 16 · 2015: 6 · 2014: 10 · 2013: 12 · 2012: 14
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Institutes for BioMedical Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- preclinical cancer models, translational oncology, anticancer drug development, drug attrition, clinical trial failure, patient selection
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Drug Evaluation, Preclinical, Genetic Engineering, Humans, Models, Biological, Neoplasms, Cell Line, Tumor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.